The Modern Rules Of Stamets Microdose Protocol

With regard to hallucinogens such as psilocybin — an ingredient of so-called "magic mushrooms" (e.g., Psilocybe cubensis) - it may be time to reconsider long-term theories related to their actions in the human brain.

Although psilocin (an active metabolite of psilocybin) (Fig. 1A) and other ancient hallucinogens such as lysergic acid diethylamide (LSD) have complex chemistry closely related to many neurotransmitter receptors (1), it has long been reported. that their psychedelic actions are best related. with 5-HT2A – serotonin receptor agonism.

https://youtu.be/IBLnSl8Q1NQ

Indeed, in

5-HT2A knockout mice, old hallucinogens are inactive. Importantly, the psychedelic actions of psilocybin in stamets microdose protocol are eliminated with previous treatment by selected 5-HT2A antagonists.

Taken together, these findings support the view that psilocybin and other anti-hallucinogens exert their psychedelic actions in humans by activating 5-HT2A serotonin receptors.

Although there is

Some consensus about the pharmacological actions of classical hallucinogens, the neuronal mechanisms underlying the psychedelic actions of hallucinogens remain controversial.

• Thus, some researchers have
• Noted that LSD-like
• Hallucinogens can enhance
• Pyramidal neuron activity
• By activating 5-HT2A
• Serotonin receptor signaling

These findings that

Hallucinogens using glutamatergic neurotransmission are consistent with many other thegaiavoice.com showing that 5-HT2A receptors are secreted in Layer V glutamatergic neurons (9) although we and others have noted that 5-HT2A receptors are available in GABA-ergic interneurons. Indeed, 5-HT2A agonists may also increase inhibitory neuronal activity.

Taken together

these previous findings have suggested that hallucinogens such as psilocybin may be due to a The Gaia Voice of actions on both stimulants (e.g., pyramidal) and inhibitory (e.g., GABA-ergic interneuronal) neuronal. circuits (Fig. 1C).

Thus, speculatively

Hallucinogens such as psilocybin can create their psychedelic effects by increasing the excitatory or inhibitory neuronal activity in humans. Unfortunately, due to medical, legal, occupational, and social concerns, well-controlled studies of mushroom activity in humans have been debilitating since the early 1960s.

Carhart-Harris successfully conducted important research that begins to fill our gaps regarding hallucinogen actions in humans. Surprisingly, they show that psilocybin reduces signaling effects on neuronal activity [brain blood flow and oxygen-dependent signals (BOLD)] in key stamets microdose protocol of the brain involved in psychedelic drug reactions. They also report that psilocybin appears to reduce brain “interaction” as measured by pharmaco-physiological interactions.